Health
A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population, – EurekAlert
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called ”bad” cholesterol–by 50 percent in patients with severe…
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called “bad” cholesterol–by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored by Regeneron, are being presented as “late breaking science” at the American Heart Association Scientific Sessions 2020 on Sunday,…
-
General14 hours agoMildura man given 28 years to pay $73,000 in unpaid fines and tolls
-
General17 hours agoAustralia’s race to rewire the country amid a global transmission boom is not unique
-
Noosa News4 hours agoThe grey backstreet of Brisbane’s Fortitude Valley where Arnie the missing dog was found dead in his owner Nathan McKeown’s black ute
-
General22 hours agoPrincess Diana enters Paris waxwork museum in ‘revenge dress’